Safety and Efficacy of Cyclophosphamide, Sorafenib, Bevacizumab, and Atezolizumab in Pediatric Solid Tumor Patients

Safety and Efficacy of Cyclophosphamide, Sorafenib, Bevacizumab, and Atezolizumab in Pediatric Solid Tumor Patients
Conditions:   Refractory Solid Tumor;   Hepatocellular Carcinoma;   Malignant Solid Tumor;   Pediatric Cancer;   Pediatric Solid Tumor
Interventions:   Drug: Atezolizumab;   Drug: Sorafenib;   Drug: Bevacizumab;   Drug: Cyclophosphamide
Sponsor:   St. Jude Children’s Research Hospital
**RECRUITING NOW**

Source: View full study details on ClinicalTrials.gov

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. By listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.

July 22, 2022Comments OffClinicalTrials.gov | Oncology Clinical Trials | Oncology Studies | US National Library of Medicine
Comments